Aurinia Pharmaceuticals Inc.
General ticker "AUPH" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.3B (TTM average)
Aurinia Pharmaceuticals Inc. follows the US Stock Market performance with the rate: 55.4%.
Estimated limits based on current volatility of 2.7%: low 14.22$, high 15.00$
Factors to consider:
- Total employees count: 130 (+261.1%) as of 2024
- US accounted for 89.4% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Strategic risks and growth management, Regulatory and compliance, Market volatility, Single product reliance, Cybersecurity threats
- Price in estimated range
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [10.70$, 19.47$]
- 2026-12-31 to 2027-12-31 estimated range: [10.13$, 18.60$]
Financial Metrics affecting the AUPH estimates:
- Positive: with PPE of 7.7 at the end of fiscal year the price was low
- Positive: Operating profit margin, % of 37.06 > 18.38
- Negative: Inventory ratio change, % of 2.37 > 0.80
- Positive: Return on assets ratio (scaled to [-100,100]) of 27.65 > 6.11
- Negative: -0.16 < Industry inventory ratio change (median), % of 0
- Negative: negative Industry operating income (median)
- Positive: Shareholder equity ratio, % of 77.35 > 64.29
- Positive: Interest expense per share per price, % of 0.20 <= 0.73
Short-term AUPH quotes
Long-term AUPH plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $167.13MM | $239.48MM | $283.06MM |
| Operating Expenses | $258.82MM | $244.17MM | $178.14MM |
| Operating Income | $-91.69MM | $-4.69MM | $104.91MM |
| Non-Operating Income | $14.22MM | $12.13MM | $9.24MM |
| Interest Expense | $2.77MM | $4.83MM | $4.33MM |
| R&D Expense | $49.64MM | $20.79MM | $32.51MM |
| Income(Loss) | $-77.47MM | $7.45MM | $114.16MM |
| Taxes | $0.55MM | $1.70MM | $-173.04MM |
| Profit(Loss)* | $-78.02MM | $5.75MM | $287.20MM |
| Stockholders Equity | $377.95MM | $377.48MM | $581.33MM |
| Inventory | $39.70MM | $39.23MM | $45.69MM |
| Assets | $548.06MM | $550.64MM | $751.59MM |
| Operating Cash Flow | $-33.46MM | $44.39MM | $135.66MM |
| Capital expenditure | $0.72MM | $0.28MM | $0.25MM |
| Investing Cash Flow | $-6.71MM | $39.26MM | $-32.77MM |
| Financing Cash Flow | $-5.13MM | $-49.09MM | $-106.11MM |
| Earnings Per Share** | $-0.54 | $0.04 | $2.14 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.